Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01250470
Show Display Options
Rank Status Study
1 Completed Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Conditions: Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Giant Cell Glioblastoma;   Glioblastoma;   Gliosarcoma;   Mixed Glioma;   Recurrent Brain Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Montanide ISA-51/Survivin Peptide Vaccine;   Biological: Sargramostim

Indicates status has not been verified in more than two years